GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Cyclically Adjusted Revenue per Share

ORGS (Orgenesis) Cyclically Adjusted Revenue per Share : $0.90 (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orgenesis's adjusted revenue per share for the three months ended in Jun. 2024 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.90 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Orgenesis's average Cyclically Adjusted Revenue Growth Rate was -8.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Orgenesis was 8.40% per year. The lowest was -4.80% per year. And the median was 8.10% per year.

As of today (2024-09-20), Orgenesis's current stock price is $0.5118. Orgenesis's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was $0.90. Orgenesis's Cyclically Adjusted PS Ratio of today is 0.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orgenesis was 11.07. The lowest was 0.30. And the median was 3.75.


Orgenesis Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Orgenesis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Cyclically Adjusted Revenue per Share Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 0.73 0.89 1.01 0.93

Orgenesis Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.96 0.93 0.92 0.90

Competitive Comparison of Orgenesis's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PS Ratio falls into.



Orgenesis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orgenesis's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.006/132.5538*132.5538
=0.006

Current CPI (Jun. 2024) = 132.5538.

Orgenesis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201408 0.000 100.352 0.000
201411 0.000 99.635 0.000
201502 0.000 99.032 0.000
201505 0.157 100.333 0.207
201508 0.199 100.548 0.262
201511 0.261 100.135 0.346
201602 0.177 100.040 0.235
201605 0.126 101.355 0.165
201608 0.200 101.617 0.261
201611 0.275 101.829 0.358
201702 0.199 102.779 0.257
201705 0.240 103.256 0.308
201708 0.247 103.587 0.316
201711 0.326 104.072 0.415
201802 0.245 105.052 0.309
201805 0.303 106.148 0.378
201808 0.434 106.383 0.541
201811 0.382 106.338 0.476
201903 0.469 107.251 0.580
201906 0.071 108.070 0.087
201909 0.569 108.329 0.696
201912 -1.263 108.420 -1.544
202003 0.106 108.902 0.129
202006 0.081 108.767 0.099
202009 0.078 109.815 0.094
202012 0.096 109.897 0.116
202103 0.388 111.754 0.460
202106 0.433 114.631 0.501
202109 0.357 115.734 0.409
202112 0.284 117.630 0.320
202203 0.293 121.301 0.320
202206 0.290 125.017 0.307
202209 0.314 125.227 0.332
202212 0.533 125.222 0.564
202303 0.005 127.348 0.005
202306 0.004 128.729 0.004
202309 0.004 129.860 0.004
202312 0.006 129.419 0.006
202403 0.004 131.776 0.004
202406 0.006 132.554 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Orgenesis  (NAS:ORGS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orgenesis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.5118/0.9
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orgenesis was 11.07. The lowest was 0.30. And the median was 3.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orgenesis Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Orgenesis's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452